Real-World Clinical and Economic Efficacy of Succinate-Based Therapy with Remaxol of Alcohol Hepatitis

Abstract

A real-world study with clinical and economic assessment of the use of succinate-containing drugs in patients with alcoholic liver disease was conducted. The study was based on data from Buyanov City Clinical Hospital in Moscow and Mirotvortsev Clinical Hospital in Saratov. The period of the study was from 2019 to 2022. The main analyzed factor was the duration of hospitalization and 60 patients with alcoholic liver disease and blood transaminases exceeding two norms and blood ammonia more than one and a half norms were included in the study. Of 60 patients 36 used succinate-containing drugs as part of complex therapy (main group) and 24 did not receive them (control group).The dynamics of indicators of clinical and instrumental status of patients did not differ in both groups (V=0.35; F=0.87; p=0.614). The modelling by Markov chains was performed. The use of succinate-containing drugs demonstrated 8.3 % reducing of costs per case of alcoholic liver disease cure due to the average reduction of hospitalization by 2.42 days.